Recent developments in molecular profiling of bladder cancer.

Curr Opin Urol

Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark.

Published: September 2006

Purpose Of Review: Profiling bladder tumors using high-density microarrays has recently become possible. We review recent reports on the use of profiling for the prediction of various clinical courses in bladder cancer. We also stress the methods and materials needed to translate such molecular profiles into clinically useful tests.

Recent Findings: Using gene expression microarrays, it has been possible to identify signatures that predict various properties of bladder cancer such as stage, grade, progression, and likelihood of metastases. Using arrays for genomic instability, similar properties have been examined, but the effectiveness seems to be less than that of gene expression. Some of genes identified also work as predictors using immunohistochemistry.

Summary: The signatures or molecular profiles for some of these arrays are now being tested in multicenter studies with the purpose of introducing these into the clinic, for planning of follow-up and treatment selection.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.mou.0000240313.16324.d3DOI Listing

Publication Analysis

Top Keywords

bladder cancer
12
profiling bladder
8
molecular profiles
8
gene expression
8
developments molecular
4
molecular profiling
4
bladder
4
cancer purpose
4
purpose review
4
review profiling
4

Similar Publications

European cancer mortality predictions for the year 2025 with focus on breast cancer.

Ann Oncol

February 2025

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. Electronic address:

Background: We predicted the number of cancer deaths and rates for 2025 in the European Union (EU), its five most populous countries, and the UK, focusing on breast cancer.

Materials And Methods: We derived population data and death certificates for all cancers and major sites for the EU, France, Germany, Italy, Poland, Spain, and the UK since 1970, from the World Health Organization and United Nations databases. Estimates for 2025 were computed by linear regression on recent trends identified through Poisson joinpoint regression, considering the slope of the most recent trend segment.

View Article and Find Full Text PDF

A machine learning-based prognostic signature utilizing MSC proteomics for predicting bladder cancer prognosis and treatment response.

Transl Oncol

March 2025

Institute of Urology, Lanzhou University Second Hospital, Key Laboratory of Gansu Province for Urological Diseases, Gansu Urological Clinical Center, Lanzhou, China. Electronic address:

Background: Mesenchymal stem cells (MSCs), due to their tumor-targeting homing properties, are present in the tumor microenvironment (TME) and influence the biological behaviors of tumors. The purpose of this paper is to establish a signature based on the MSC secretome to predict the prognosis and treatment of bladder cancer (BLCA).

Methods: The presence of MSCs in BLCA was validated through flow cytometry and multiplex fluorescence immunohistochemistry (mFIHC), and the relationships between MSCs and clinical characteristics were explored.

View Article and Find Full Text PDF

In Japan, several workers were diagnosed with bladder cancer 10-40 years after exposure to 4,4'-methylenebis(2-chloroaniline) (MOCA), mainly through the skin. MOCA also induces bladder cancer in dogs and nonbladder (breast, liver, lung) cancers in rodents. MOCA with S9 fractions contains mutagenic metabolites after catalysis by N-acetyl transferase (NAT).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!